Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer

A new study has revealed that a combination of chemotherapy and treatment with two drugs, Perjeta and Herceptin, lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months. Lead researcher Dr. Sandra M. Swain said, "We've never seen results like this before in HER2-positive metastatic breast cancer. This unprecedented data gives patients with an aggressive disease hope to live a longer, better life." During ...

Read More

You have just read an article categorized health titled Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer.

Written by: editor - Thursday, February 19, 2015